Jeremy M . Shefner, MD, PhD

Department

Neurology (Phoenix)

Position

Professor

Books

• Handbook of Clinical Neurology
  Andrews Jinsy A., Clinical neurophysiology of anterior horn cell disorders [Book Chapter] 2019

Publications

• Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
  Shefner Jeremy M., A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis
  20:7-8, p. 584 - 594 2019
• Neurology
  Andrews Jinsy A., ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment
  93:2, p. 66 - 71 2019
• Neurology
  Darras Basil T., Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies
  92:21, p. e2492 - e2506 2019
• Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
  Rutkove Seward B., ALS longitudinal studies with frequent data collection at home: study design and baseline data
  20:1-2, p. 61 - 67 2019
• Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
  Shefner Jeremy M., Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system
  19:7-8, p. 555 - 561 2018
• Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
  Lechtzin Noah, Respiratory measures in amyotrophic lateral sclerosis
  19:5-6, p. 321 - 330 2018
• European Journal of Neurology
  Smith R. A., Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale)
  25:7, p. 907 - e66 2018
• Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
  Andrews Jinsy A., VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics
  19:3-4, p. 259 - 266 2018
• Brooks Benjamin Rix, Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion 2018
• Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
  Meng Lisa, Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance
  19:1-2, p. 134 - 142 2018
• JAMA Neurology
  Andrews Jinsy A., Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis
  75:1, p. 58 - 58 2018

Presentations

• Invited Speaker, 2019 California ALS Summit, Irvine CA. 2019
• Invited Speaker, 2018 Northeast ALS Clinical Trials Consortium Annual Meeting, Clearwater FL. 2018
• Plenary Speaker, 2018 FightMND Australasion ALS Symposium, Melbourne, Australia. 2018
• Lisa Krivickas Lecturer, Massachusetts General Hospital, Boston, MA. 2018
• Invited Speaker, Packard Symposium on ALS, Baltimore, MD. 2017
• Grand Rounds, Houston Methodist Medical Center. 2017
• Grand Rounds, University of Arizona College of Medicine. 2017

Other

• Speech Analysis in ALS Patients with and without Cognitive Abnormalities: Evaluation of Sensitivity and Disease Progression

• Treat ALS NEALS Clinical Trials Network. Goal: to facilitate the performance of investigator initiated ALS trials.

• A Phase 2 study of CK107 in Patients with Amyotrophic Lateral Sclerosis (ALS) Goal: To determine the safety and preliminary efficacy of treatment of CK107 in ALS patients.

• Fluid Biomarkers with Deep Phenotyping in Patients with ALS. Goal: To discover fluid markers that correlate with specific aspects of decline in ALS patients.

• ALS AT HOME: Measuring ALS Progression using home based outcome measures. Goal: to reduce variability of standard outcome measures using frequent sampling and to test a paradigm whereby patients can participate in clinical trials remote from a study site.